Role for runt-related transcription factor 2 in proliferative and calcified vascular lesions in pulmonary arterial hypertension

American Journal of Respiratory and Critical Care Medicine

Volumn 194, Issue 10, 2016, Pages 1273-1285

  Ruffenach, Gregoire ^a   Chabot, Sophie ^a   Tanguay, Virginie F ^a   Courboulin, Audrey ^b   Boucherat, Olivier ^a   Potus, Francois ^a   Meloche, Jolyane ^a   Pflieger, Aude ^a   Breuils Bonnet, Sandra ^a   Nadeau, Valerie ^a   Paradis, Renee ^a   Tremblay, Eve ^a   Girerd, Barbara ^b   Hautefort, Aurelie ^b   Montani, David ^b   Fadel, Elie ^b   Dorfmuller, Peter ^b   Humbert, Marc ^b   Perros, Frederic ^a,b   Paulin, Roxane ^a   Provencher, Steeve ^a   Bonnet, Sebastien ^a   more..

^a LAVAL UNIVERSITY   (Canada)

^b Universite Paris Sud   (France)

Author keywords

Calcification; Hypoxia inducible factor 1 ; Pulmonary artery smooth muscle cells; Pulmonary hypertension; Vascular remodeling

Indexed keywords

CALCIUM; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MCIRORNA 204; MICRORNA; PROTEIN INHIBITOR; S 173204; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG; RUNX2 PROTEIN, HUMAN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTERY CALCIFICATION; ARTERY LESION; ARTICLE; BIOMINERALIZATION; CELL CULTURE; CELL ISOLATION; CELL PROLIFERATION; CELL TRANSDIFFERENTIATION; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GAIN OF FUNCTION MUTATION; GENE EXPRESSION; HEART RIGHT VENTRICLE FUNCTION; HEMODYNAMIC PARAMETERS; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA-INDUCED PULMONARY HYPERTENSION; IN VITRO STUDY; LOSS OF FUNCTION MUTATION; LUNG BLOOD VESSEL; LUNG PARENCHYMA; MALE; MOLECULAR PATHOLOGY; NEBULIZATION; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PULMONARY ARTERY SMOOTH MUSCLE CELL; PULMONARY HYPERTENSION; RAT; UPREGULATION; VASCULAR REMODELING; BLOOD VESSEL CALCIFICATION; GENETICS; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADULT; CELL PROLIFERATION; CORE BINDING FACTOR ALPHA 1 SUBUNIT; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; VASCULAR CALCIFICATION;

EID: 84999006747     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201512-2380OC     Document Type: Article

References (43)

1. Leopold JA. Vascular calcification: mechanisms of vascular smooth muscle cell calcification. Trends Cardiovasc Med 2015;25:267-274.
2. Cui RR, Li SJ, Liu LJ, Yi L, Liang QH, Zhu X, Liu GY, Liu Y, Wu SS, Liao XB, et al. MicroRNA-204 regulates vascular smooth muscle cell calcification in vitro and in vivo. Cardiovasc Res 2012;96: 320-329.
3. Idelevich A, Rais Y, Monsonego-Ornan E. Bone Gla protein increases HIF-1a-dependent glucose metabolism and induces cartilage and vascular calcification. Arterioscler Thromb Vasc Biol 2011;31: e55-e71.
4. Li G, Lu WH, Ai R, Yang JH, Chen F, Tang ZZ. The relationship between serum hypoxia-inducible factor 1a and coronary artery calcification in asymptomatic type 2 diabetic patients. Cardiovasc Diabetol 2014; 13:52.
5. Ozaki T, Wu D, Sugimoto H, Nagase H, Nakagawara A. Runt-related transcription factor 2 (RUNX2) inhibits p53-dependent apoptosis through the collaboration with HDAC6 in response to DNA damage. Cell Death Dis 2013;4:e610.
6. Tandon M, ChenZ, Pratap J. Runx2 activates PI3K/Akt signalng via mTORC2 regulation in invasive breast cancer cels. Breast Cancer Res 2014;16:16.
7. Kwon TG, Zhao X, Yang Q, Li Y, Ge C, Zhao G, Franceschi RT. Physical and functional interactions between Runx2 and HIF-1a induce vascular endothelial growth factor gene expression. J Cell Biochem 2011;112:3582-3593.
8. Lee SH, Che X, Jeong JH, Choi JY, Lee YJ, Lee YH, Bae SC, Lee YM. Runx2 protein stabilizes hypoxia-inducible factor-1a through competition with von Hippel-Lindau protein (pVHL) and stimulates angiogenesis in growth plate hypertrophic chondrocytes. J Biol Chem 2012;287: 14760-14771.
9. Bonnet S, Michelakis ED, Porter CJ, Andrade-Navarro MA, Thébaud B, Bonnet S, Haromy A, Harry G, Moudgil R, McMurtry MS, et al. An abnormal mitochondrial-hypoxia inducible factor-1alpha-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats: similarities to human pulmonary arterial hypertension. Circulation 2006;113:2630-2641.
10. Lambert CM, Roy M, Robitaille GA, Richard DE, Bonnet S. HIF-1 inhibition decreases systemic vascular remodelling diseases by promoting apoptosis through a hexokinase 2-dependent mechanism. Cardiovasc Res 2010;88:196-204.
11. Galiè N, Humbert M, Vachiery J-L, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, et al.; The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2015;46:903-975.
12. Sutendra G, Dromparis P, Wright P, Bonnet S, Haromy A, Hao Z, McMurtry MS, Michalak M, Vance JE, Sessa WC, et al. The role of Nogo and the mitochondria-endoplasmic reticulum unit in pulmonary hypertension. Sci Transl Med 2011;3:88ra55.
13. Meloche J, Courchesne A, Barrier M, Carter S, Bisserier M, Paulin R, Lauzon-Joset JF, Breuils-Bonnet S, Tremblay É, Biardel S, et al. Critical role for the advanced glycation end-products receptor in pulmonary arterial hypertension etiology. J Am Heart Assoc 2013;2: e005157.
14. Meloche J, Pflieger A, Vaillancourt M, Paulin R, Potus F, Zervopoulos S, Graydon C, Courboulin A, Breuils-Bonnet S, Tremblay E, et al. Role for DNA damage signaling in pulmonary arterial hypertension. Circulation 2014;129:786-797.
15. Federici C, Drake KM, Rigelsky CM, McNelly LN, Meade SL, Comhair SA, Erzurum SC, Aldred MA. Increased mutagen sensitivity and DNA damage in pulmonary arterial hypertension. Am J Respir Crit Care Med 2015;192:219-228.
16. Courboulin A, Paulin R, Giguère NJ, Saksouk N, Perreault T, Meloche J, Paquet ER, Biardel S, Provencher S, Côté J, et al. Role for miR-204 in human pulmonary arterial hypertension. J Exp Med 2011;208: 535-548.
17. Abdul-Salam VB, Wharton J, Cupitt J, Berryman M, Edwards RJ, Wilkins MR. Proteomic analysis of lung tissues from patients with pulmonary arterial hypertension. Circulation 2010;122: 2058-2067.
18. Meloche J, Potus F, Vaillancourt M, Bourgeois A, Johnson I, Deschamps L, Chabot S, Ruffenach G, Henry S, Breuils-Bonnet S, et al. Bromodomain-containing protein 4: the epigenetic origin of pulmonary arterial hypertension. Circ Res 2015;117:525-535.
19. Potus F, Ruffenach G, Dahou A, Thebault C, Breuils-Bonnet S, Tremblay È, Nadeau V, Paradis R, Graydon C, Wong R, et al. Downregulation of microRNA-126 contributes to the failing right ventricle in pulmonary arterial hypertension. Circulation 2015;132: 932-943.
20. Bertero T, Lu Y, Annis S, Hale A, Bhat B, Saggar R, Saggar R, Wallace WD, Ross DJ, Vargas SO, et al. Systems-level regulation of microRNA networks by miR-130/301 promotes pulmonary hypertension. J Clin Invest 2014;124:3514-3528.
21. Komori T. Regulation of bone development and extracellular matrix protein genes by RUNX2. Cell Tissue Res 2010;339:189-195.
22. Welch RD, Jones AL, Bucholz RW, Reinert CM, Tjia JS, Pierce WA, Wozney JM, Li XJ. Effect of recombinant human bone morphogenetic protein-2 on fracture healing in a goat tibial fracture model. J Bone Miner Res 1998;13:1483-1490.
23. Niederhoffer N, Lartaud-Idjouadiene I, Giummelly P, Duvivier C, Peslin R, Atkinson J. Calcification of medial elastic fibers and aortic elasticity. Hypertension 1997;29:999-1006.
24. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 2010;55: 1318-1327.
25. Rajaram S, Swift AJ, Condliffe R, Johns C, Elliot CA, Hill C, Davies C, Hurdman J, Sabroe I, Wild JM, et al. CT features of pulmonary arterial hypertension and its major subtypes: a systematic CT evaluation of 292 patients from the ASPIRE Registry. Thorax 2015; 70:382-387.
26. Mahapatra S, Nishimura RA, Sorajja P, Cha S, McGoon MD. Relationship of pulmonary arterial capacitance and mortality in idiopathic pulmonary arterial hypertension. J Am Coll Cardiol 2006; 47:799-803.
27. Blyth KG, Syyed R, Chalmers J, Foster JE, Saba T, Naeije R, Melot C, Peacock AJ. Pulmonary arterial pulse pressure and mortality in pulmonary arterial hypertension. Respir Med 2007;101:2495-2501.
28. Campo A, Mathai SC, Le Pavec J, Zaiman AL, Hummers LK, Boyce D, Housten T, Champion HC, Lechtzin N, Wigley FM, et al. Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am J Respir Crit Care Med 2010; 182:252-260.
29. Pellegrini P, Rossi A, Pasotti M, Raineri C, Cicoira M, Bonapace S, Dini FL, Temporelli PL, Vassanelli C, Vanderpool R, et al. Prognostic relevance of pulmonary arterial compliance in patients with chronic heart failure. Chest 2014;145:1064-1070.
30. Saouti N, Westerhof N, Helderman F, Marcus JT, Boonstra A, Postmus PE, Vonk-Noordegraaf A. Right ventricular oscillatory power is a constant fraction of total power irrespective of pulmonary artery pressure. Am J Respir Crit Care Med 2010;182:1315-1320.
31. Mok MY, Lau CS, Chiu SS, Tso AW, Lo Y, Law LS, Mak KF, Wong WS, Khong PL, Lam KS. Systemic sclerosis is an independent risk factor for increased coronary artery calcium deposition. Arthritis Rheum 2011;63:1387-1395.
32. Lim M, Zhong C, Yang S, Bell AM, Cohen MB, Roy-Burman P. Runx2 regulates survivin expression in prostate cancer cells. Lab Invest 2010;90:222-233.
33. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008;8:61-70.
34. Archer SL, Gomberg-Maitland M, Maitland ML, Rich S, Garcia JG, Weir EK. Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-ROS-HIF-1a-Kv1.5 O2-sensing pathway at the intersection of pulmonary hypertension and cancer. Am J Physiol Heart Circ Physiol 2008;294:H570-H578.
35. Koga T, Matsui Y, Asagiri M, Kodama T, de Crombrugghe B, Nakashima K, Takayanagi H. NFAT and osterix cooperatively regulate bone formation. Nat Med 2005;11:880-885.
36. Stern PH. The calcineurin-NFAT pathway and bone: intriguing new findings. Mol Interv 2006;6:193-196.
37. Bonnet S, Rochefort G, Sutendra G, Archer SL, Haromy A, Webster L, Hashimoto K, Bonnet SN, Michelakis ED. The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted. Proc Natl Acad Sci USA 2007;104:11418-11423.
38. Huang Q, Jiang Z, Meng T, Yin H, Wang J, Wan W, Cheng M, Yan W, Liu T, Song D, et al. MiR-30a inhibits osteolysis by targeting RunX2 in giant cell tumor of bone. Biochem Biophys Res Commun 2014;453:160-165.
39. Taipaleenmäki H, Browne G, Akech J, Zustin J, van Wijnen AJ, Stein JL, Hesse E, Stein GS, Lian JB. Targeting of Runx2 by miR-135 and miR-203 impairs progression of breast cancer and metastatic bone disease. Cancer Res 2015;75:1433-1444.
40. Zhang J, Zheng B, Zhou PP, Zhang RN, He M, Yang Z, Wen JK. Vascular calcification is coupled with phenotypic conversion of vascular smooth muscle cells through Klf5-mediated transactivation of the Runx2 promoter. Biosci Rep 2014;34:e00148.
41. Tanikawa T, Okada Y, Tanikawa R, Tanaka Y. Advanced glycation end products induce calcification of vascular smooth muscle cells through RAGE/p38 MAPK. J Vasc Res 2009;46:572-580.
42. Moser B, Megerle A, Bekos C, Janik S, Szerafin T, Birner P, Schiefer AI, Mildner M, Lang I, Skoro-Sajer N, et al. Local and systemic RAGE axis changes in pulmonary hypertension: CTEPH and iPAH. Plos One 2014;9:e106440.
43. Courboulin A, Tremblay VL, Barrier M, Meloche J, Jacob MH, Chapolard M, Bisserier M, Paulin R, Lambert C, Provencher S, et al. Krüppel-like factor 5 contributes to pulmonary artery smooth muscle proliferation and resistance to apoptosis in human pulmonary arterial hypertension. Respir Res 2011;12:128.